2016 Fiscal Year Final Research Report
Synegic effect of paclitaxel protein-bound particles in malignant melanomas.
Project/Area Number |
15K19701
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
Dermatology
|
Research Institution | Iwate Medical University |
Principal Investigator |
|
Project Period (FY) |
2015-04-01 – 2017-03-31
|
Keywords | 悪性黒色腫 / BCL2 / paclitaxel / 分子標的治療薬 |
Outline of Final Research Achievements |
Malignant melanoma is refractory to antitubulin agents. Treatment of the paclitaxel-resistant cell lines combined paclitaxel protein-bound particles for injectable suspension with ABT-737, an inhibitor of BCL2 and BCLxL, or simultaneous knock-down of BCL2 and BCLxL dramatically increased the cells' sensitivity, while knock-down of MCL1, another member of the BCL2 family, had only a minimal effect. Our results demonstrated the new combination therapy for malignant melanomas.
|
Free Research Field |
皮膚科学
|